<DOC>
	<DOCNO>NCT00060710</DOCNO>
	<brief_summary>The purpose study determine efficacy CP-461 give twice daily orally patient advance metastatic malignant melanoma evaluate safety profile CP-461 patient population .</brief_summary>
	<brief_title>CP-461 Treatment Patients With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm malignant melanoma advance metastatic . Patients may receive 2 prior systemic chemotherapy regimen ( include dacarbazine , alternative dosing schedule temozolomide ) . The last chemotherapy must least 4 week prior study drug administration . Prior radiation therapy allow . Radiotherapy must complete least 4 week prior study drug administration . Patients may receive prior surgery . At least 4 week must elapse patient must recover side effect associate surgery . Patients measurable disease . At least one bidimensionally measurable lesion clearly define margin document : medical photograph skin oral lesion , plain Xray least one diameter 0.5 cm great , CT , MRI , palpation diameter 2 cm great . A radiated bony lesion may consider evaluable lesion , unless evidence disease progression site prior administration study drug . Clinical parameter : Life expectancy &gt; 2 month , Age &gt; 18 year , ECOG performance status 02 Patients adequate organ function relate following : White count &gt; 3000/ul , Platelet count &gt; 70,000/ul , Hemoglobin &gt; 8 g/l , Bilirubin WNL , AST ALT &lt; 2.5 x ULN , Creatinine &lt; 1.5 x ULN 24 hour creatinine clearance &gt; 60 ml/min There acute infection require systemic antibiotic . Informed consent : Each patient must completely aware nature his/her disease process must willingly give consent inform procedure follow , experimental nature therapy , alternative , potential benefit , sideeffects , risk , discomfort . Subjects brain metastasis . More 2 prior chemotherapy regimens treatment advanced melanoma . Chemotherapy within four week prior study drug administration . Radiation therapy great equal 50 % bone marrow . Patients must prior radiotherapy area measurable disease unless clearly progressive disease site measurable disease outside area prior radiation . Insufficient recovery active toxicity prior therapy . Subjects poor medical risk active nonmalignant systemic disease . Frequent vomit medical condition could interfere oral medication intake ( e.g . partial bowel obstruction ) . No prior malignancy curatively treat carcinoma insitu cervix skin cancer . If opinion treat physician , sufficient time elapse , extremely likely patient cure prior malignancy , patient may eligible protocol . No serious medical psychiatric illness prevent informed consent intensive treatment ( e.g . serious infection ) . HIV status severe illness assess use medical record . Pregnant nursing woman . Both woman men must take adequate precaution prevent pregnancy treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>melanoma</keyword>
</DOC>